Goldman Sachs Delays Fed Rate Cut Forecast to 2026 Amid Rising Inflation Concerns 
Asian Stocks Rise Despite Middle East Tensions as Chipmakers Boost Markets 
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman 
OpenAI-Microsoft Deal Sets $38 Billion Revenue-Sharing Cap Ahead of Potential IPO 
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026 
China vs. NASA: The New Moon Race and What's at Stake by 2030 
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Trump Administration Releases New UFO Files and Apollo Mission Records 
US Stock Futures Hold Steady Ahead of CPI Data and Iran Conflict Concerns 
Trump Invites Top CEOs Including Nvidia, Apple, Boeing to China Summit With Xi Jinping 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
Trump Rejects Iran Proposal as Strait of Hormuz Crisis Pushes Oil Prices Higher 
US, Japan Reaffirm Strong Currency Coordination Amid Yen Volatility 
Researchers from the Korea Advanced Institute of Science and Technology (KAIST) have developed a wearable green organic light-emitting diode (OLED) with a 470-nanometer (nm) wavelength that can cure jaundice in infants.
The OLED provides sufficient power for jaundice treatment even at low voltage, durability for over 100 hours of operation, a low operating temperature of less than 35 Celsius degrees, and flexibility that can endure over 1,000 bends at a 2 mm radius of curvature.
The bilirubin level of the infants’ serum reaches 12 milligrams per decilitre (mg/dL) within three hours of being exposed to the OLED, indicating the completed treatment of jaundice.
Unlike existing light-emitting diode (LED)-based jaundice treatment devices currently used at hospitals, the OLED showed uniform and effective treatment functions.
